Literature DB >> 31475299

C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Alejandro Balestracci1, Luciana Meni Bataglia2, Ismael Toledo2, Laura Beaudoin2, Caupolican Alvarado2.   

Abstract

BACKGROUND: The correlation between complement activation and severity of hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli (STEC-HUS) has been examined in few studies, with conflicting results. We investigated whether C3 levels on admission are associated with worse acute outcomes.
METHODS: Demographic, clinical, and laboratory variables were compared between dialyzed and non-dialyzed patients and between those with or without extrarenal complications. Univariate and multivariate analyses were performed; odds ratio (OR) and 95% confidence interval (95%CI) were calculated. C3 concentrations were correlated with dialysis length (Spearman test) and ROC curves with area under the curves (AUC) were calculated to identify C3 concentrations able to discriminate patients with dialysis requirements and complicated course.
RESULTS: Among 49 children, 33 had normal and 16 had decreased C3 concentrations. Higher hemoglobin, lactic dehydrogenase, urea and creatinine and lower albumin, sodium, and C3 and C4 concentrations at admission were associated with dialysis requirement; only creatinine remained significant (p = 0.03, OR 2.1, 95%CI 1.34-2.7) by multivariate analysis. Patients with a complicated course presented higher leukocyte count, hemoglobin and lactic dehydrogenase and lower albumin, sodium, and C3 and C4. In the multivariate analysis, leukocyte count (p = 0.02, OR 2.6, 95%CI 1.4-4.3) and C3 concentration (p = 0.039, OR 1.7, 95%CI 1.1-2.73) were independently associated with a complicated disease. C3 levels correlated with dialysis length (r = - 0.42, p = 0.002); nevertheless, they were unable to discriminate dialysis requirement (AUC = 0.25, 95%CI 0.11-0.38) and extrarenal complications (AUC = 0.24, 95%CI 0.11-0.4).
CONCLUSIONS: Our study suggests that decreased C3 levels at admission are associated with a more complicated STEC-HUS episode.

Entities:  

Keywords:  C3; Complement activation; Escherichia coli; Hemolytic uremic syndrome; Shiga toxin

Mesh:

Substances:

Year:  2019        PMID: 31475299     DOI: 10.1007/s00467-019-04334-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  44 in total

1.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

Review 2.  Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis.

Authors:  Rita S Suri; William F Clark; Nick Barrowman; Jeffrey L Mahon; Heather R Thiessen-Philbrook; M Patricia Rosas-Arellano; Kelly Zarnke; Jocelyn S Garland; Amit X Garg
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

3.  Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Lisa Sartz; Diana Karpman
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

4.  Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura.

Authors:  J S Cameron; R Vick
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

5.  Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.

Authors:  Ayşe Ağbaş; Nilüfer Göknar; Nurver Akıncı; Zeynep Yürük Yıldırım; Mehmet Taşdemir; Meryem Benzer; İbrahim Gökçe; Cengiz Candan; Nuran Küçük; Selçuk Uzuner; Gül Özçelik; Demet Demirkol; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2018-08-29       Impact factor: 3.714

6.  The complement system in hemolytic-uremic syndrome in childhood.

Authors:  L Monnens; J Molenaar; P H Lambert; W Proesmans; P van Munster
Journal:  Clin Nephrol       Date:  1980-04       Impact factor: 0.975

Review 7.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

8.  Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.

Authors:  Joshua M Thurman; Russell Marians; Woodruff Emlen; Susan Wood; Christopher Smith; Hillary Akana; V Michael Holers; Martin Lesser; Myriam Kline; Cathy Hoffman; Erica Christen; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

9.  Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome.

Authors:  W L Robson; A K Leung; G H Fick; A I McKenna
Journal:  Nephron       Date:  1992       Impact factor: 2.847

Review 10.  Management of hemolytic-uremic syndrome in children.

Authors:  Silviu Grisaru
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-06-12
View more
  5 in total

1.  HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.

Authors:  Carla Galvez; Paola Krall; Alejandro Rojas; Jun Oh; Francisco Cano
Journal:  Pediatr Nephrol       Date:  2022-08-15       Impact factor: 3.651

2.  Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli.

Authors:  Jorge Goldstein; Krista Nuñez-Goluboay; Alipio Pinto
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 3.  Thrombotic microangiopathy in children.

Authors:  Lilian Monteiro P Palma; Maria Helena Vaisbich-Guimarães; Meera Sridharan; Cheryl L Tran; Sanjeev Sethi
Journal:  Pediatr Nephrol       Date:  2022-01-18       Impact factor: 3.651

4.  Hemolytic uremic syndrome due to Shiga toxin–producing Escherichia coli and hypocomplementemia with favorable response to eculizumab: a case report

Authors:  Alejandro Balestracci; Luciana Meni Battaglia; Sandra Mariel Martin; Ismael Toledo; Iris Puyol; Laura Beaudoin; Natalia Luján Robledo
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-06-28

5.  Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).

Authors:  Sebastian Loos; Jun Oh; Laura van de Loo; Markus J Kemper; Martin Blohm; Raphael Schild
Journal:  Pediatr Nephrol       Date:  2021-05-27       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.